Literature DB >> 32935872

SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease.

Thomas J Gniadek1, Joshua M Thiede2, William E Matchett3, Abigail R Gress2, Kathryn A Pape3, Jessica K Fiege3, Marc K Jenkins3, Vineet D Menachery4, Ryan A Langlois3, Tyler D Bold2.   

Abstract

BACKGROUND: The transfer of passive immunity with convalescent plasma is a promising strategy for treatment and prevention of COVID-19, but donors with a history of nonsevere disease are serologically heterogenous. The relationship between SARS-Cov-2 antigen-binding activity and neutralization activity in this population of donors has not been defined. STUDY DESIGN AND METHODS: Convalescent plasma units from 47 individuals with a history of nonsevere COVID-19 were assessed for antigen-binding activity of using three clinical diagnostic serology assays (Beckman, DiaSorin, and Roche) with different SARS-CoV-2 targets. These results were compared with functional neutralization activity using a fluorescent reporter strain of SARS-CoV-2 in a microwell assay.
RESULTS: Positive correlations of varying strength (Spearman r = 0.37-0.52) between antigen binding and viral neutralization were identified. Donors age 48 to 75 years had the highest neutralization activity. Units in the highest tertile of binding activity for each assay were enriched (75%-82%) for those with the highest levels of neutralization.
CONCLUSION: The strength of the relationship between antigen-binding activity and neutralization varies depending on the clinical assay used. Units in the highest tertile of binding activity for each assay are predominantly comprised of those with the greatest neutralization activity.
© 2020 AABB.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32935872      PMCID: PMC7995753          DOI: 10.1111/trf.16101

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  15 in total

1.  Antibody responses to SARS-CoV-2 in patients with COVID-19.

Authors:  Quan-Xin Long; Bai-Zhong Liu; Hai-Jun Deng; Gui-Cheng Wu; Kun Deng; Yao-Kai Chen; Pu Liao; Jing-Fu Qiu; Yong Lin; Xue-Fei Cai; De-Qiang Wang; Yuan Hu; Ji-Hua Ren; Ni Tang; Yin-Yin Xu; Li-Hua Yu; Zhan Mo; Fang Gong; Xiao-Li Zhang; Wen-Guang Tian; Li Hu; Xian-Xiang Zhang; Jiang-Lin Xiang; Hong-Xin Du; Hua-Wen Liu; Chun-Hui Lang; Xiao-He Luo; Shao-Bo Wu; Xiao-Ping Cui; Zheng Zhou; Man-Man Zhu; Jing Wang; Cheng-Jun Xue; Xiao-Feng Li; Li Wang; Zhi-Jie Li; Kun Wang; Chang-Chun Niu; Qing-Jun Yang; Xiao-Jun Tang; Yong Zhang; Xia-Mao Liu; Jin-Jing Li; De-Chun Zhang; Fan Zhang; Ping Liu; Jun Yuan; Qin Li; Jie-Li Hu; Juan Chen; Ai-Long Huang
Journal:  Nat Med       Date:  2020-04-29       Impact factor: 53.440

2.  Virological assessment of hospitalized patients with COVID-2019.

Authors:  Roman Wölfel; Victor M Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Müller; Daniela Niemeyer; Terry C Jones; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Journal:  Nature       Date:  2020-04-01       Impact factor: 49.962

Review 3.  Deployment of convalescent plasma for the prevention and treatment of COVID-19.

Authors:  Evan M Bloch; Shmuel Shoham; Arturo Casadevall; Bruce S Sachais; Beth Shaz; Jeffrey L Winters; Camille van Buskirk; Brenda J Grossman; Michael Joyner; Jeffrey P Henderson; Andrew Pekosz; Bryan Lau; Amy Wesolowski; Louis Katz; Hua Shan; Paul G Auwaerter; David Thomas; David J Sullivan; Nigel Paneth; Eric Gehrie; Steven Spitalnik; Eldad A Hod; Lewis Pollack; Wayne T Nicholson; Liise-Anne Pirofski; Jeffrey A Bailey; Aaron Ar Tobian
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

4.  Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.

Authors:  Katharine H D Crawford; Rachel Eguia; Adam S Dingens; Andrea N Loes; Keara D Malone; Caitlin R Wolf; Helen Y Chu; M Alejandra Tortorici; David Veesler; Michael Murphy; Deleah Pettie; Neil P King; Alejandro B Balazs; Jesse D Bloom
Journal:  Viruses       Date:  2020-05-06       Impact factor: 5.048

5.  Characteristics of Adult Outpatients and Inpatients with COVID-19 - 11 Academic Medical Centers, United States, March-May 2020.

Authors:  Mark W Tenforde; Erica Billig Rose; Christopher J Lindsell; Nathan I Shapiro; D Clark Files; Kevin W Gibbs; Matthew E Prekker; Jay S Steingrub; Howard A Smithline; Michelle N Gong; Michael S Aboodi; Matthew C Exline; Daniel J Henning; Jennifer G Wilson; Akram Khan; Nida Qadir; William B Stubblefield; Manish M Patel; Wesley H Self; Leora R Feldstein
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-07-03       Impact factor: 17.586

6.  Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients.

Authors:  Xiaoli Wang; Xianghua Guo; Qianqian Xin; Yang Pan; Yaling Hu; Jing Li; Yanhui Chu; Yingmei Feng; Quanyi Wang
Journal:  Clin Infect Dis       Date:  2020-12-17       Impact factor: 9.079

7.  SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup.

Authors:  Daniel Stadlbauer; Fatima Amanat; Veronika Chromikova; Kaijun Jiang; Shirin Strohmeier; Guha Asthagiri Arunkumar; Jessica Tan; Disha Bhavsar; Christina Capuano; Ericka Kirkpatrick; Philip Meade; Ruhi Nichalle Brito; Catherine Teo; Meagan McMahon; Viviana Simon; Florian Krammer
Journal:  Curr Protoc Microbiol       Date:  2020-06

8.  Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.

Authors:  Jeremia M Coish; Adam J MacNeil
Journal:  Microbes Infect       Date:  2020-06-24       Impact factor: 2.700

9.  An Infectious cDNA Clone of SARS-CoV-2.

Authors:  Xuping Xie; Antonio Muruato; Kumari G Lokugamage; Krishna Narayanan; Xianwen Zhang; Jing Zou; Jianying Liu; Craig Schindewolf; Nathen E Bopp; Patricia V Aguilar; Kenneth S Plante; Scott C Weaver; Shinji Makino; James W LeDuc; Vineet D Menachery; Pei-Yong Shi
Journal:  Cell Host Microbe       Date:  2020-04-13       Impact factor: 21.023

10.  A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.

Authors:  Antonio E Muruato; Camila R Fontes-Garfias; Ping Ren; Mariano A Garcia-Blanco; Vineet D Menachery; Xuping Xie; Pei-Yong Shi
Journal:  Nat Commun       Date:  2020-08-13       Impact factor: 14.919

View more
  14 in total

1.  Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.

Authors:  Aaron A R Tobian; Oliver Laeyendecker; Eshan U Patel; Evan M Bloch; William Clarke; Yu-Hsiang Hsieh; Denali Boon; Yolanda Eby; Reinaldo E Fernandez; Owen R Baker; Morgan Keruly; Charles S Kirby; Ethan Klock; Kirsten Littlefield; Jernelle Miller; Haley A Schmidt; Philip Sullivan; Estelle Piwowar-Manning; Ruchee Shrestha; Andrew D Redd; Richard E Rothman; David Sullivan; Shmuel Shoham; Arturo Casadevall; Thomas C Quinn; Andrew Pekosz
Journal:  J Clin Microbiol       Date:  2021-01-21       Impact factor: 5.948

2.  Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.

Authors:  Henry T Peng; Shawn G Rhind; Andrew Beckett
Journal:  JMIR Public Health Surveill       Date:  2021-04-07

3.  Comparative analysis of three laboratory based serological assays for SARS-CoV-2 in an Australian cohort.

Authors:  N Davidson; J Evans; D Giammichele; H Powell; P Hobson; B Teis; H Glover; K B Guppy-Coles; J Robson
Journal:  Pathology       Date:  2020-09-30       Impact factor: 5.306

4.  Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.

Authors:  Stephan Schlickeiser; Tatjana Schwarz; Sophie Steiner; Kirsten Wittke; Nabeel Al Besher; Oliver Meyer; Ulrich Kalus; Axel Pruß; Florian Kurth; Thomas Zoller; Martin Witzenrath; Leif Erik Sander; Marcel A Müller; Carmen Scheibenbogen; Hans-Dieter Volk; Christian Drosten; Victor M Corman; Leif G Hanitsch
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

5.  Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.

Authors:  Alena J Markmann; Natasa Giallourou; D Ryan Bhowmik; Yixuan J Hou; Aaron Lerner; David R Martinez; Lakshmanane Premkumar; Heather Root; David van Duin; Sonia Napravnik; Stephen D Graham; Quique Guerra; Rajendra Raut; Christos J Petropoulos; Terri Wrin; Caleb Cornaby; John Schmitz; JoAnn Kuruc; Susan Weiss; Yara Park; Ralph Baric; Aravinda M de Silva; David M Margolis; Luther A Bartelt
Journal:  mSphere       Date:  2021-08-25       Impact factor: 4.389

6.  Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.

Authors:  Hanora A Van Ert; Dana W Bohan; Kai Rogers; Mohammad Fili; Roberth A Rojas Chávez; Enya Qing; Changze Han; Spencer Dempewolf; Guiping Hu; Nathan Schwery; Kristina Sevcik; Natalie Ruggio; Devlin Boyt; Michael A Pentella; Tom Gallagher; J Brooks Jackson; Anna E Merrill; C Michael Knudson; Grant D Brown; Wendy Maury; Hillel Haim
Journal:  Microbiol Spectr       Date:  2022-01-26

7.  Demographic and Clinical Factors Associated with Reactivity of Anti-SARS-CoV-2 Antibodies in Serbian Convalescent Plasma Donors.

Authors:  Jasmina Grujić; Nevenka Bujandrić; Zorana Budakov-Obradović; Vladimir Dolinaj; Damir Bogdan; Nebojša Savić; Alejandro Cabezas-Cruz; Dragana Mijatović; Verica Simin; Nikola Anđelić; Pavle Banović
Journal:  Int J Environ Res Public Health       Date:  2021-12-21       Impact factor: 3.390

Review 8.  Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy.

Authors:  Daniele Focosi; Fabrizio Maggi; Paola Mazzetti; Mauro Pistello
Journal:  Rev Med Virol       Date:  2020-09-21       Impact factor: 11.043

9.  Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test.

Authors:  Václav Šimánek; Ladislav Pecen; Zuzana Krátká; Tomáš Fürst; Hana Řezáčková; Ondřej Topolčan; Karel Fajfrlík; Dalibor Sedláček; Robin Šín; Petr Pazdiora; Hana Zelená; David Slouka; Radek Kučera
Journal:  Diagnostics (Basel)       Date:  2021-03-25

10.  Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.

Authors:  Sixten Körper; Bernd Jahrsdörfer; Victor M Corman; Jan Pilch; Patrick Wuchter; Rainer Blasczyk; Rebecca Müller; Torsten Tonn; Tamam Bakchoul; Richard Schäfer; David Juhl; Tatjana Schwarz; Nina Gödecke; Thomas Burkhardt; Michael Schmidt; Thomas Appl; Hermann Eichler; Harald Klüter; Christian Drosten; Erhard Seifried; Hubert Schrezenmeier
Journal:  Transfus Med Hemother       Date:  2021-04-21       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.